First Participant dosed in Ph 3 Study (Neoshot) of IBI310 + Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy April 2, 2024
Positive Findings announced from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research March 26, 2024
CheckMate -9DW Trial of Opdivo + Yervoy Meets Primary Endpoint of OS for the 1L Treatment of Advanced HCC March 26, 2024
PT886 granted Fast Track designation for the treatment of patients with metastatic claudin 18.2-positive pancreatic adenocarcinoma by the FDA March 26, 2024
Global Ph 3 Clinical Trial for Cholangiocarcinoma Authorized in the EU and Orphan Drug Designation for Tinengotinib to Treat Biliary Tract Cancer Granted by EMA March 19, 2024
FDA clears INDs for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b March 19, 2024
FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy March 19, 2024
New clinical data from 2L ONSEMBLE trial provides further evidence of the efficacy of onvansertib + FOLFIRI/bev in bev naïve RAS-mutated mCRC patients March 12, 2024
Global Ph 3 Trial for Cholangiocarcinoma Authorized in the EU and Orphan Drug Designation for Tinengotinib Granted by EMA March 12, 2024
DURIPANC Ph 1b/2 clinical trial of Ampligen with Imfinzi for the treatment of pancreatic cancer opened for enrollment and enrolled first subject March 4, 2024
BLA for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA March 4, 2024
Onivyde regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA February 26, 2024
US regulatory approval received to start pancreatic cancer Ph IIb trial with nadunolimab February 26, 2024
First Refractory Gastric Cancer Patient Dosed in Ph 2 Trial with Allogeneic INKT Cell Therapy and Botensilimab and Balstilimab February 26, 2024
First Subject Dosed in Ph 1b/2 Study of Ampligen® + Imfinzi for the Treatment of Pancreatic Cancer February 26, 2024
Immune-Onc Therapeutics Announces Clinical Trial Collaboration with Roche to Evaluate IO-108 in Ph 1b/2 Study for 1L Treatment of HCC February 26, 2024
US FDA approval of Onivyde® (Irinotecan Liposome Injection) + NALIRIFOX for 1L mPDAC triggers a $225M milestone payment from Ipsen to Merrimack February 26, 2024